Immuneering (IMRX) Equity Ratio (2020 - 2024)
Historic Equity Ratio for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to 0.84.
- Immuneering's Equity Ratio fell 782.27% to 0.84 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.84, marking a year-over-year decrease of 782.27%. This contributed to the annual value of 0.88 for FY2023, which is 164.5% down from last year.
- As of Q3 2024, Immuneering's Equity Ratio stood at 0.84, which was down 782.27% from 0.86 recorded in Q2 2024.
- Immuneering's Equity Ratio's 5-year high stood at 0.96 during Q3 2021, with a 5-year trough of 0.66 in Q2 2021.
- Moreover, its 5-year median value for Equity Ratio was 0.91 (2023), whereas its average is 0.7.
- As far as peak fluctuations go, Immuneering's Equity Ratio soared by 25991.46% in 2021, and later crashed by 782.27% in 2024.
- Immuneering's Equity Ratio (Quarter) stood at 0.59 in 2020, then surged by 259.91% to 0.94 in 2021, then decreased by 4.06% to 0.9 in 2022, then decreased by 1.65% to 0.88 in 2023, then dropped by 4.64% to 0.84 in 2024.
- Its Equity Ratio was 0.84 in Q3 2024, compared to 0.86 in Q2 2024 and 0.89 in Q1 2024.